458 related articles for article (PubMed ID: 10086481)
1. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression.
Gorman JM; Kent JM
J Clin Psychiatry; 1999; 60 Suppl 4():33-8; discussion 39. PubMed ID: 10086481
[TBL] [Abstract][Full Text] [Related]
2. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Zohar J; Westenberg HG
Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934
[TBL] [Abstract][Full Text] [Related]
3. Overview of antidepressants currently used to treat anxiety disorders.
Feighner JP
J Clin Psychiatry; 1999; 60 Suppl 22():18-22. PubMed ID: 10634351
[TBL] [Abstract][Full Text] [Related]
4. [Current drug treatment. Effects of antidepressive agents in nervous and stress-related disorders].
Rosenberg R
Ugeskr Laeger; 2001 Apr; 163(14):1985-91. PubMed ID: 11307357
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
Frazer A
J Clin Psychiatry; 2001; 62 Suppl 12():16-23. PubMed ID: 11430614
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt DP; McClellan KJ
Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
[TBL] [Abstract][Full Text] [Related]
9. Where are we going with SSRIs?
Isaac M
Eur Neuropsychopharmacol; 1999 Jul; 9 Suppl 3():S101-6. PubMed ID: 10523065
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of reboxetine in major depression.
Schatzberg AF
J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression].
Semba J
Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):79-84. PubMed ID: 10976459
[TBL] [Abstract][Full Text] [Related]
12. The pharmacologic treatment of anxiety disorders: a review of progress.
Ravindran LN; Stein MB
J Clin Psychiatry; 2010 Jul; 71(7):839-54. PubMed ID: 20667290
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin-reuptake inhibitors: an update.
Masand PS; Gupta S
Harv Rev Psychiatry; 1999; 7(2):69-84. PubMed ID: 10471245
[TBL] [Abstract][Full Text] [Related]
14. Norepinephrine involvement in antidepressant action.
Frazer A
J Clin Psychiatry; 2000; 61 Suppl 10():25-30. PubMed ID: 10910014
[TBL] [Abstract][Full Text] [Related]
15. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.
Stahl SM
J Affect Disord; 1998 Dec; 51(3):215-35. PubMed ID: 10333979
[TBL] [Abstract][Full Text] [Related]
17. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?
Ribot R; Ouyang B; Kanner AM
Epilepsy Behav; 2017 May; 70(Pt A):5-9. PubMed ID: 28407526
[TBL] [Abstract][Full Text] [Related]
18. [Biological basis of anxiety disorders and serotonergic anxiolytics].
Inoue T; Izumi T; Li XB; Huang JZ; Kitaichi Y; Nakagawa S; Koyama T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Jun; 24(3):125-31. PubMed ID: 15291241
[TBL] [Abstract][Full Text] [Related]
19. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
Machado M; Iskedjian M; Ruiz I; Einarson TR
Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
[TBL] [Abstract][Full Text] [Related]
20. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
Gunasekara NS; Noble S; Benfield P
Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
